TW201200506A - Novel process - Google Patents
Novel process Download PDFInfo
- Publication number
- TW201200506A TW201200506A TW100118793A TW100118793A TW201200506A TW 201200506 A TW201200506 A TW 201200506A TW 100118793 A TW100118793 A TW 100118793A TW 100118793 A TW100118793 A TW 100118793A TW 201200506 A TW201200506 A TW 201200506A
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- butyl
- reaction
- bis
- nbu
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- -1 di-n-butylamino-3-propoxy Chemical group 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- 239000002841 Lewis acid Substances 0.000 claims description 9
- 150000007517 lewis acids Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 6
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 238000010520 demethylation reaction Methods 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 230000017858 demethylation Effects 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 claims 1
- UODZKAAILJVZGF-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarbonyl chloride Chemical compound ClC(=O)CC(O)(CC(Cl)=O)C(Cl)=O UODZKAAILJVZGF-UHFFFAOYSA-N 0.000 claims 1
- 241000270666 Testudines Species 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- OXNGKCPRVRBHPO-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O OXNGKCPRVRBHPO-XLMUYGLTSA-N 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 14
- 229960002084 dronedarone Drugs 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- IXADHCVQNVXURI-UHFFFAOYSA-N 1,1-dichlorodecane Chemical compound CCCCCCCCCC(Cl)Cl IXADHCVQNVXURI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000002309 gasification Methods 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JCMVPOVHKWWBAU-UHFFFAOYSA-N 1,2-dichlorohydrazine Chemical compound ClNNCl JCMVPOVHKWWBAU-UHFFFAOYSA-N 0.000 description 1
- VJTVCCVWOKGBCL-UHFFFAOYSA-N 1-(dibutylamino)propan-2-one Chemical compound CCCCN(CC(C)=O)CCCC VJTVCCVWOKGBCL-UHFFFAOYSA-N 0.000 description 1
- SPPUXULYIUEQMC-UHFFFAOYSA-N 4-[3-(dibutylazaniumyl)propoxy]benzoate Chemical compound CCCCN(CCCC)CCCOC1=CC=C(C(O)=O)C=C1 SPPUXULYIUEQMC-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- ANLMKUQEPXRMGV-UHFFFAOYSA-N n-butyl-n-(3-chloropropyl)butan-1-amine Chemical compound CCCCN(CCCC)CCCCl ANLMKUQEPXRMGV-UHFFFAOYSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
201200506 六、發明說明: 【發明所屬之技術領域】 本發明為一種新穎的方法,用以製備N-[2-正丁基 -3-{4-[(3-二·正丁基胺基)-丙氧基]-苯甲醯基}-1-苯呋喃 -5-yl]-甲院-續化醯胺(決奈達隆,dronedarone)以及其醫 學上可接受鹽類,以及其使用在本方法中的新穎中間 【先前技術】
,(CH
nBu
Me—SO nBu 具有式I的決奈達隆(Dronedarone)可用於治療心血 管系統的某些病理變化’首先是治療心絞痛、高血壓、 心律不整和腦血流不足(EP 0471609 B1) 目前幾種用以製備具有式I之決奈達隆 (Dronedarone)的方法是已知的。在—項先前技術方法 (EP 0471609 B1)中,具有式^^之孓正丁基_5氮_苯呋 喃
與大菌㈣氯在綠德爾_克拉絲條件下反應,並藉 由在二氣化鋁的存在下加熱所產生具有式X之正丁 201200506 基-3-(4-甲乳基-苯曱酸基)-5-氮-苯咬喃
XI 而得到具有式XI之2-正丁基-3-(4-羥基-苯曱醯基)-5-氮-苯15夫喃。 然而,以工業規模利用這種反應步驟會涉及許多困 難,因為具有式X之化合物是致突變的,且三氯化鋁對 於健康是有害的。將產生具有式XI之化合物與二-正丁 基胺基-氣丙烷反應得到具有式XII之2-正丁基-3-[4-(3-二-正丁基胺基-丙氧基)-苯曱酿基]-5-氣-苯咬喃
.nBu N
I
nBu XII 其中,在與氧化鉑觸媒進行還原作用後得到具有式XIII 之5-胺基-2-正丁基-3-[4-(3-二-正丁基胺基-丙氧基)-苯 曱醯基]-苯呋喃。 . 201200506
XIII 、 ^nBu (ch2)3、n/ nBu 最後,曱磺醯化反應具有式XIII之化合物得到具 有式I之決奈達隆(Dronedarone)。 這是線性合成,其中部份理想分子逐步建立起來, 在連續的步驟中使用越來越多複雜的分子’而這是不經 濟的。 在最後的步驟,使具有式XIII之化合物之胺基進 行選擇性曱磺醯化是困難的,亦生成具有式II之雙曱 磺醯化2-正丁基-3-[(二-正丁基胺基-3-丙氧基)-笨曱醯 基]-5-雙-(曱磺醯胺基)-苯呋喃衍生物,並且其伴隨出現 具有式I之決奈達隆(Dronedarone) 〇
II 根據文獻資料,在經過管柱層析純化後,此方法可得到 61.6%之產率,但是此方法是複雜的,不適合於χ業廣 用0 在公開第WO 0248132號的專利申請案中提到另外 一個方法用以製備決奈達隆(Dronedarone)。這 種超收斂 途徑由以下步驟所組成: 具有式XIV之5-胺基-2-正丁基-苯°夫喃 6 201200506
是經過曱顧化且所得具有式XV之2·正丁基_5曱碍 醯胺基-苯呋喃 ’
XV
Me 在弗裡德_ _克拉夫茨條件下與具有式VIII之4-[3-(二_ 丁土胺基)丙氧基]-本甲醯基氯化物的氣化氫鹽類 應
CI
(ch2)3\ ^nBu
N
I nBu
VIII 而知到/、有式I之決奈達隆(Dronedarone)的氯化氫趟 類。 風 在此種方法中,反應步驟的次序有變動,合成反應 的-開始是還原仙以及曱續醯化反應步驟。 至於其反應步驟數量,此方法非常簡單且有經濟效 益。然而,其缺點是在最後一個步驟中,決奈達隆 (Dronedaron^的氣化氳鹽類以相當受汙染的形式得 到。這可以藉由在弗裡德爾·克拉夫茨反應中存在的二 丁基胺基·•丙基而解釋。在w〇〇2/48132的例子中,其 產率為90%’其起初為粗決奈達隆(Dr〇nedar〇ne)氯化氮 201200506 鹽’接著在異丙醇中以氣化氫溶液處理的純化步驟中, 可獲得純化的決奈達隆(D ronedarone)氯化氫鹽(90%)。 思味著粗決奈達隆(Dronedarone)氯化氫的產率是 90% ’然後純化步驟的產率是90%。丰方法的另外一個 缺點是,在弗裡德爾-克拉夫茨反應中所使用的反應物 以及獲得的副產物在水中是不可溶的,因此它們無法藉 由水相清洗從系統中移除。 【發明内容】 我們的目標是實現此新穎的方法,用以製備決奈達 隆(Dronedarone)以及其醫學上可接受鹽類,其中本方法 避免上述提到已知方法之缺點,並且是有經濟效益以及 工業可利用的。 我們已經發現,如果具有式Η之2_正丁基_3_[(二_ 正丁基胺基-3-丙氧基)-苯曱醯基]_5_雙_(甲磺醯胺基)_ 苯呋喃的曱磺醯基之一者
L擇f生地斷裂,則具有式I之決奈達隆(Dr〇ne(jar〇ne)可 在良好的產率以及適當的純度下得到。 根據我們的發明,在醇類溶劑或在醇類溶劑混合物 中,當鹼金屬醇化物存在下,進行具有式H之化合物 的甲%酉盘基之一者的斷裂。至於醇類溶劑,可使用曱 8 201200506 醇、乙醇或是它們的混合物。至於鹼金屬醇化物,可施 加曱醇鈉、甲醇鉀、乙醇納或乙醇鉀。 依據本發明一實施例之方法,具有式III之2-正丁 基-5-雙-(甲磺醯胺基)-苯呋喃
Me— s〇2
在弗裡德爾-克拉夫茨條件下與大茴香醯氯反應,且所 得具有式VII之2-正丁基-5-雙-(甲磺醯胺基)-3-(4-曱氧 基-苯甲醯基)-苯呋喃
Me——SO
Me—SO, 2\c γγ- o nBu
OMe
VII 去曱基化,且因此所獲得具有式VI之2-正丁基-3-(4-羥基-苯曱醯基)-5-雙-(曱磺醯胺基)-苯呋喃 Me——SO,
Me—S02
VI 與具有式V之3-二-正丁基胺基-氯丙烷進行反應, 9 201200506 Q|^(CH2) Bu
N nBu
V 以及從所得具有式II之2-正丁基-3-[(二-正丁基胺基-3-丙氧基)-苯曱醯基]-5-雙-(甲磺醯胺基)-苯呋喃
II 曱磺醯基之一者藉由上述提到之方法選擇性地斷裂。 依據本發明中的另一個實施例之方法,具有式III 之2-正丁基-5-(雙-曱續酿胺基)-苯α夫喃·
Me—so, 2\
III nBu
/N
Me——S02 在弗裡德爾-克拉夫茨條件下與具有式VIII之4-(3-二-正丁基胺基-丙氧基)-苯曱酸的氣化氫鹽反應,
CI
nBu nBu
VIII 以及接著從而獲得具有式II之2-正丁基-3-[(二-正丁基 胺基-3-丙氧基)-苯曱酿基]-5-雙-(曱石黃酿胺基)-苯α夫喃 201200506
曱石K醯基之一者藉由上述提到之方法選擇性地斷裂。 依據本發明,在惰性有機溶劑中或惰性有機溶劑混 合物中,進行具有< 111之反應物與大@香醯氣的反 應。至於惰性有機溶劑,可施加_化有機溶劑(二氣甲 烷、二氯乙烷、氯苯)。 #在路易斯酸存在時,進行具有式ΗΙ之化合物與大 ,香酿氣的反應。至於路易斯酸,可施加最大有5個當 量數的氯化鐵(III)或氣化鋁。 在惰性有機溶劑中或惰性有機溶劑混合物中,進行 =有式VII之化合物的去甲基化反應。至於惰性有機溶 ㈣,可施加鹵化有機溶劑(二氯甲院'二氯乙烧、氯苯)。 在路㈣酸存在時,騎具有式νπ之化合物的去 土化反應。至於路易斯酸,可施加氯化鐵⑽或氣化 進行具有式VII之化合物 在20-100。(:的溫度下 的去甲基化反應。 機⑻巾或有機溶劑混合物巾,進行具有式1 物Γ反應。至於有機溶劑,可施加低碳 酮丁員甲醇、乙醇)或者是低碳原子數的酮類(丙 酮、丁酮)。 11 1 ㈣性储財訂,實施具有式 s物的反應。至於具有基本特性的酸性 201200506 黏結劑,可使用無機碳酸鹽。 在所施加之溶劑以及溶劑混合物的沸點之溫度附 近,進行具有式V和VI之化合物的反應。 在惰性有機溶劑中或惰性有機溶劑混合物中,進行 具有式III以及VIII之化合物的反應。至於惰性有機溶 劑,可施加鹵化有機溶劑(二氯曱烷、二氯乙烷、氯苯)。 在路易斯酸存在時,可進行具有式III以及VIII 之化合物的反應。至於路易斯酸,可施加氯化鐵(ΙΠ)或 氯化铭。 從文獻中(EP 0471609 B1,實施例35以及實施列 70)已知由2-正丁基-5-氮-苯呋喃製備具有式II之2-正 丁基-3-[(二-正丁基胺基-3-丙氧基)-苯甲醯基]-5-雙-(曱 磺醯胺基)-苯呋喃以及具有式III之2-正丁基-5-雙-(曱 石黃酿胺基)-苯α夫β南。 具有式VI之2-正丁基-3-(4-羥基-苯曱醯基)-5-雙 -(曱磺醯胺基)-苯呋喃 Me—- ·ςη
以及具有式VII之2-正丁基-5-雙-(曱磺醯胺基)-3-(4-曱 氧基-苯曱醯基)-苯呋喃 12 2〇12〇〇5〇6
VII 二斤頭化合物,且在文獻中它們是未知的。 【實施方式】 r,=以下的實施列中說明本發明的更進一步的細 p旦並非將申請人之申請專利範圍限制在實施例中。 實施例1 I [2-正+丁基_3_{4 [(3•二正丁基胺基丙氧基]-苯甲酷 土} 1-苯呋喃_5_基]_曱烷_磺化醯胺(J) 由5g的納以及17〇ml純乙醇而製得的溶液添加到 7g 2-正丁基-3-[(二-正丁基胺基)-3-丙氧基)-4-苯甲醯 基]-5-雙-(甲續酿胺基)_苯呋喃(11)。反應混合物煮沸3〇 分鐘後’接著減壓揮發。將3〇ml二氯曱烷以及5〇ml 水加到殘留物中,並且攪拌此混合物2〇分鐘,相會分 離’有機相以20ml的水清洗並揮發。 產物:油(產率:97_9°/〇)。純度(HPLC) : 93.1% 產物經由其草酸鹽類純化(產率:90.3%)。純度(HPLC): 99.5%。 !Η NMR(DMSO): 0.8-0.9 ppm (m, 9H) 1 1.2-1.5 ppm (m, 10H) ; 1.67 ppm (5% 2H) ; 1.87 ppm (5% 2H) ; 2.38 ppm (t, J=7.2Hz, 4H) ; 2.57 ppm (m, 2H) ; 2.81 ppm (t, J=7.5Hz, 13 201200506 2H) ; 2.91 ppm (s, 3H) ; 4.15 ppm (t, J=6.2Hz, 2H) ; 7.09 (d, J=8.8Hz, 2H) ; 7.24 ppm (dd, J=8.9; 2.2Hz, 1H) ; 7.34 ppm (d, J=2.1Hz, 1H) ; 7.65 ppm (d, J=8.8Hz, 1H) ; 7.81 ppm (d, J=8.8Hz, 2H) 實施例2 N-[2-正丁基-3-{4-[(3-二-正丁基胺基)-丙氧基]-苯曱醯 基}·_1-苯σ夫喃-5-基]-曱烧-橫化酿胺(I) 執行實施例1中的方法,其不同處為使用曱醇,而 不是乙醇。 純化後產率:88.6%。純度(HPLC) : 99.7%。 實施例3 Ν-[2-正丁基-3-{4-[(3-二-正丁基胺基)-丙.乳基]-笨曱酿 基}·_1-苯°夫喃-5-基]-曱烧-續化驢胺(I) 執行實施例1中的方法,其不同處為使用鉀,而不 是鈉。 純化後產率:88.9%。純度(HPLC) : 99.5%。 實施例4 Ν-[2-正丁基-3-{4-[(3-二-正丁基胺基)-丙氧基]-苯曱醯 基}-1-苯°夫喃-5-基]-甲炫-續化酿胺(I) 溶解在220ml純乙醇的0.8g鈉金屬加至22g含有 4%二曱磺醯氨基化合物(II)的未純化決奈達隆 (dronedarone)(I)中。反應混合物煮沸30分鐘後,接著 揮發。將140ml水以及80ml二氣甲烷加到殘留物中, 14 201200506 並且攪拌此混合物20分鐘。相會分離,接著二氯曱烷 相揮發。粗決奈達隆(dronedarone)(I)經由其草酸鹽類純 化。 純化後產率:93.5%。純度(HPLC) : 99.4%。 實施例5 2-正丁基-5-雙-(曱磺醯胺基)-3-(4-甲氧基-苯曱醯基)_苯 呋喃(VII) 4 g 2-正丁基-5-雙-(甲石黃醮胺基)-笨α夫喃(ijj)以及 2.29 g大茴香醯氣於2〇ml二氯曱烷中攪拌溶解。溶液 降溫至5-10°C以及在此溫度下,在15分鐘内將2.16 g 氯化鐵(III)分四部分加入。混合物加熱至2〇°c且在該 溫度下攪拌1小時。接著反應混合物加熱至4〇cc,且 在此溫度下於30分鐘内加入30ml的水。在此溫度下相 會分離。二氣曱烷相以10ml的水,2 χίο ml的5%水 性碳酸氫鈉溶液以及2 xlO ml的水清洗。二氯曱烷相揮 發。 產物:油(產率:95.98%)。純度(HPLC) : 99.0〇/〇。 H NMR (DMSO-d6): 7.86 ppm (d, J=8.6Hz, 2H) ; 7 80 ppm (d, J=8.7Hz, 1H) ; 7.55 ppm (d, J= 1.9Hz, 1H) ϊ 7 51 ppm (dd, J= 8.7Hz, 2.0Hz, 1H) ; 7.12 ppm (d> j=8.7Hz5 2H) ; 3.9 ppm (s, 3H) ; 3.53 ppm (s, 6H) ; 2.84 ppm (t, J= 7.4Hz, 2H) ; 1.7 ppm (5\ J= 7.3Hz, 2H) ; 1,27 ppm (6\ J=7.4 Hz, 2H) ; 083 ppm (t, J= 7.4Hz, 3H) 分子質量:[M+H]+ 計算:480.1151 Da; [M+H]+ 測量. 480.1142 Da。 15 201200506 實施例6 2-正丁基-3-(4-羥基-苯曱醯基)-5-雙-(甲磺醯胺基)-苯呋 喃(VI) 5.3 g 2-正丁基-5-雙-(曱磺醯胺基)-3-(4-曱氧基-苯 甲醯基)-苯呋喃(VII)在12ml氯苯中溶解。接著溶液在 溫度為64-66。(:加入含有4.44 g氣化鋁以及17ml氣苯 的懸浮相中,因此溶液的一半量在30分鐘内加入而剩 餘的另一半量在3小時内加入。在添加後,混合物在 64-66°C下攪拌4小時,並在該溫度下1〇分鐘内加入 25ml的水。此相是熱分離。氣苯相在65〇c下與3 X 25 ml 的水進行攪拌’產生相分離且有機相揮發。 產物:油(產率:94.0%)。純度(HPLC) : 99.0%。 NMR(DMSO): 0.84 ppm (t, J=7,4Hz, 3H) ; 1.27 ppm (6’,J=7.3Hz,2H) ; 1.70 ppm (5,,J=7.4Hz,2H) ; 2.85 ppm (t,J=7,3Hz,2H); 3.53 ppm (s,6H); 6.93 ppm (s,J=8.5Hz, 2H) ; 7.50 ppm (dd, J=8.6Hz, 1.8Hz, 1H) ; 7.54 ppm (d, J=l-9Hz, 1H) ; 7.77 ppm (d, J=8.5Hz, 2H) ; 7.79 ppm (d, J=8.7Hz, 1H) ; 10.54 ppm (s, 1H) 分子質量:[M+H]+ 計算:466.0994 Da; [M+H]+ 測量: 466.1001 Da。 實施例7 2-正丁基-3-(4-經基-笨曱醯基)_5-雙_(曱磺醯胺基)_笨呋 喃(VI) 依據實施例6中的方法執行,其中不同處為使用二 氣曱規作為溶劑。 201200506 純化後產率:97.0%。純度(HPLC) : 99.1%。 實施例8 2-正丁基[(二·正丁基胺基·3_丙氧基)_4_苯曱醯基]_5_ 雙-(甲磺醯胺基)-苯呋喃(II) 2 g的2-正丁基_3-(4-羥基-苯曱醯基)-5-雙-(曱磺醯 胺基)-笨呋喃(V)以及0.88 g的(3-二-正丁基胺基)-氣丙 烧溶解在16ml的丁酮中。1.75 g的碳酸卸加入至溶液 中’且反應混合物煮沸8小時。無機鹽類過濾移除,以 16ml 丁酮清洗。藉由揮發移除溶劑。 產物:油(2.56 g,產率:93.5%)。純度(HPLC) : 99.1%。 ]H NMR (DMSO-d6): 7.87 ppm (d, J=8.8Hz, 2H) ; 7.81 ppm (d, J=8.8Hz, 1H) ; 7.53 ppm (d, J=2.3Hz, 1H) ; 7.52 ppm (dd, J=8.8; 2.3Hz, 1H) ; 7.12 ppm (d, J=8.8Hz, 2H); 4.21pp (w, 2H) ; 3.53 ppm (s, 6H); 3.26 ppm (w, 2H) ; 3.03 ppm (w, 4H) ; 2.84 ppm (t, J=7.5Hz, 2H) ; 2.19 ppm (w, 2H) ; 1.70 ppm (5% J=7.4Hz, 2H) ; 1.68 ppm (w, 4H) ; 1.36 ppm (6\ J=7.0Hz, 4H) ; 1.27 ppm (6\ J=7.3Hz, 2H) ; 0.94 ppm (t, J=7.2Hz, 6H) ; 0.84 ppm (t, J=7.4Hz, 3H) 實施例9 2-正丁基-3-[(二-正丁基胺基_3_丙氧基)_4_苯曱醯基]·5_ 雙-(甲磺醯胺基)-苯呋喃(II) 2 g的2-正丁基-5-雙-(曱磺醯胺基)-苯呋喃(m)溶 解在10 ml的二氣曱烷中,並且將1.8 g4-(二-正丁基胺 基-丙氧基)苯曱醯基氯化物(VIII)的氫氯化物加入至 17 201200506 溶液中。混合物冷卻至5°C,以及在15分鐘内將0.93 g 氯化鐵(III)分四部分加入。反應混合物加熱至20°C並 在此溫度下攪拌1小時,接著加熱至35-40°C以及加入 16ml的水至其中。在攪拌30分鐘後,會產生相分離。 二氣曱烷相在35-40°C下以6ml的水,2 X 6 ml的5% 水性碳酸氫納溶液以及2 X 60 ml的水清洗。二氯曱烧 藉由蒸發移除。 產物:油(3.5 g,產率:95.2%)。純度(HPLC) : 89.2% 此產物與實施例8所製備的化合物是相同的。 【圖式簡單說明】 無 【主要元件符號說明】 無
Claims (1)
- 201200506 七、曱請專利範圍: 1. 一種用以製備具有式I之N-[2-正丁基-3-{4-[(3-二 丁基胺基)-丙氧基]-苯曱醯基}-1-苯呋喃-5-基]-曱 烧-續化酿胺〇一(CH2)3—N /nBu ~nBu 以及其醫學上可接受鹽類的方法方法,其特徵在於 具有式II之2-正丁基-3-[(二-正丁基胺基-3-丙氧 基)-苯曱醯基]-5-雙-(曱磺醯胺基)-苯呋喃中的曱磺 酿基之一者選擇性斷裂,且如果理想的話,所得具有式I之化 合物係轉化為其鹽類。 2. 如申請專利範圍第1項所述之方法,其特徵在於該 反應是在有機溶劑或者有機溶劑混合物中進行。 3. 如申請專利範圍第1至2項中任一項所述之方法, 其特徵在於該反應是在鹼金屬醇化物的存在下進 行。 4. 如申請專利範圍第1至3項中任一項所述之方法, 其特徵在於 a)具有式III之2-正丁基-5-雙-(曱磺醯胺基)- 19 2\201200506 苯σ夫喃 Me——SO Me——S02,N III 與大菌香醯氯在路易斯酸存在下反應, 以及 b)所得具有式VII之2-正丁基-5-雙-(曱磺醯胺 基)-3-(4-曱氧基-苯曱醯基)-苯呋喃VII 去曱基化,以及 c)所得具有式VI之2-正丁基-3-(4-羥基-苯曱醯 基)-5-雙-(曱石黃酿胺基卜苯。夫喃VI 與具有式V之3-(二_正丁基-胺基)-丙基_氣化物進 行反應 20 201200506 C|/(CH ^nBu nBu V 以及 d)所得具有式h之2_正丁 基_3-丙氧基)_苯曱醯基]_5冬(;-1 丁基胺 喃的曱續醯基之一者 只醯胺基)-苯呋 Me—SO Me—SO(CH,). II 、N〆 I nBu nBu 5. 6. 7. 8. 選擇性斷裂,且如果理想的話 合物係轉化為其鹽類。 彳侍具有式1之1 如申請專利範圍第4項中反應步 徵在於反應在路易斯酸存在下進行。》,其4 如申請專利範圍第4項中反應步^ 徵在於該反應係在惰性# ,其寺 混合物中騎。性有機溶齊 如申請專利範圍第4項中反應步驟b)之方法 徵f於該反應需在溫度為2(M00〇c之間進行。… 如,利範圍第10項,之方法,其特徵在於該 施加之溶劑或者溶劑混合物㈣點溫度 如申a專利㈣S 4項巾 徵在於較輕糾麵_或㈣ 21 9. 201200506 合物中進行。 10. 如申請專利範圍第4項中反應步驟c)之方法,其特 徵在於該反應在具有基本特性之酸性黏結劑存在 下進行。 11. 如申請專利範圍第1-3項中任一項之方法,其特徵 在於 a)具有式III之2-正丁基-5-雙-(曱磺醯胺基)-苯咬β南 Me— s〇2Λ Me——S〇2 IIIVIII 在路易斯酸存在下與具有式VIII之4-(3-二·正丁基 胺基-丙氧基)-苯曱醯基氣化物的氯化氫進行反應 0 以及 b)從所得具有式II之2-正丁基-3-[(二-正丁基 胺基-3-丙氧基)-苯甲醯基]-5-雙-(曱磺醯胺基)-苯 吱喃22 II201200506 f顧基之—者選擇性斷裂,且如果理想的話,所 得具有式I之化合物係轉化為其鹽類。 12. 如申凊專利In®第4_11項或根據申料利範圍第 5項中反應步驟a)之方法,其特徵在於氯化鐵⑽ 或氯化鋁(III)係用作路易斯酸。 13. 如曱請專利範圍第 14. A ^喟甲反應步驟a)之方 ^其特徵在於該反應在龜錢溶劑或惰性有機 /谷劑混合物中進行。 :種具?式VI之2_正丁基外經基-苯甲醯基)-5-叉·-(曱石黃醯胺基)-苯咬喃裡兴有式VII 基-5-雙_(曱磺醯胺 15. 基)-3-(4-甲氧基-笨曱醯基苯呋喃 Me— SO Me-SOn :v>2^〇ζΐ ο nBu OMe 23 VII 201200506 四、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件符號簡單說明: 無 五、本案若有化學式時,請揭示最能顯示發明特徵的化學式:
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1000330A HUP1000330A2 (en) | 2010-06-18 | 2010-06-18 | Process for the preparation of dronedarone and the novel intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201200506A true TW201200506A (en) | 2012-01-01 |
Family
ID=89989791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100118793A TW201200506A (en) | 2010-06-18 | 2011-05-30 | Novel process |
Country Status (15)
Country | Link |
---|---|
US (1) | US9174958B2 (zh) |
EP (1) | EP2582685A1 (zh) |
JP (1) | JP2013528641A (zh) |
KR (1) | KR20130036282A (zh) |
CN (1) | CN103068810A (zh) |
AR (1) | AR082006A1 (zh) |
AU (1) | AU2011266805A1 (zh) |
BR (1) | BR112012032358A2 (zh) |
CA (1) | CA2802918A1 (zh) |
HU (1) | HUP1000330A2 (zh) |
MX (1) | MX2012014675A (zh) |
RU (1) | RU2013102259A (zh) |
SG (1) | SG186260A1 (zh) |
TW (1) | TW201200506A (zh) |
WO (1) | WO2011158050A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0900759A2 (en) | 2009-12-08 | 2011-11-28 | Sanofi Aventis | Novel process for producing dronedarone |
HUP1000010A2 (en) | 2010-01-08 | 2011-11-28 | Sanofi Sa | Process for producing dronedarone |
FR2958290B1 (fr) | 2010-03-30 | 2012-10-19 | Sanofi Aventis | Procede de preparation de derives de sulfonamido-benzofurane |
HUP1000330A2 (en) | 2010-06-18 | 2011-12-28 | Sanofi Sa | Process for the preparation of dronedarone and the novel intermediates |
WO2012061951A1 (zh) * | 2010-11-08 | 2012-05-18 | 山东邹平大展新材料有限公司 | 一种盐酸决奈达隆的制备方法 |
HUP1100165A2 (en) | 2011-03-29 | 2012-12-28 | Sanofi Sa | Process for preparation of dronedarone by n-butylation |
HUP1100167A2 (en) | 2011-03-29 | 2012-11-28 | Sanofi Sa | Process for preparation of dronedarone by mesylation |
WO2012171135A1 (zh) * | 2011-06-13 | 2012-12-20 | 山东邹平大展新材料有限公司 | 一种苯并呋喃化合物、其制备方法及用途 |
FR2983198B1 (fr) | 2011-11-29 | 2013-11-15 | Sanofi Sa | Procede de preparation de derives de 5-amino-benzoyl-benzofurane |
EP2617718A1 (en) | 2012-01-20 | 2013-07-24 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
WO2013124745A1 (en) | 2012-02-22 | 2013-08-29 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
US9238636B2 (en) | 2012-05-31 | 2016-01-19 | Sanofi | Process for preparation of dronedarone by Grignard reaction |
TW201536763A (zh) * | 2013-08-27 | 2015-10-01 | Gilead Sciences Inc | 製備決奈達隆或其鹽類之製程 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3577441A (en) | 1967-03-07 | 1971-05-04 | Warner Lambert Pharmaceutical | Nitro substituted benzofurans |
US3657350A (en) | 1967-05-09 | 1972-04-18 | Sterling Drug Inc | Process and compositions |
DE2337396A1 (de) | 1973-07-23 | 1975-02-13 | Hoechst Ag | Verfahren zur herstellung aromatischer 1,3-diketone |
IE45765B1 (en) | 1976-08-19 | 1982-11-17 | Ici Ltd | Triazoles and imidazoles useful as plant fungicides and growth regulating agents |
CA1260947A (en) | 1984-12-29 | 1989-09-26 | Yoshitaka Ohishi | Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same |
US5066803A (en) | 1989-12-07 | 1991-11-19 | Sterling Drug Inc. | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazines |
FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
GB9416219D0 (en) | 1994-08-11 | 1994-10-05 | Karobio Ab | Receptor ligands |
IT1275997B1 (it) | 1995-03-31 | 1997-10-24 | Great Lakes Chemical Italia | Enammine come accelleranti di vulcanizzazione per gomme naturali o sintetiche |
FR2800067B1 (fr) | 1999-10-21 | 2004-12-17 | Rhodia Chimie Sa | Intermediaires de fabrication d'un derive de type benzofurane ou benzothiophene nitre en position 5 et leurs utilisations |
WO2001029019A1 (fr) | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Procede de preparation d'un compose de type benzofurane ou benzothiophene |
FR2813308B1 (fr) | 2000-08-23 | 2005-07-01 | Sanofi Synthelabo | Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant |
FR2813306B1 (fr) | 2000-08-23 | 2005-10-21 | Sanofi Synthelabo | Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant |
FR2817864B1 (fr) * | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
FR2817865B1 (fr) * | 2000-12-11 | 2005-02-18 | Sanofi Synthelabo | Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese |
IL146389A0 (en) | 2001-11-08 | 2002-07-25 | Isp Finetech Ltd | Process for the preparation of dronedarone |
FR2833262A1 (fr) | 2001-12-06 | 2003-06-13 | Rhodia Chimie Sa | Procede de monosulfonylation d'un compose de type aminobenzofuranne ou aminobenzothiophene |
FR2833259B1 (fr) | 2001-12-10 | 2004-08-27 | Oreal | Procede de preparation de 2-arylbenzofuranes, composes intermediaires, 2-arylbenzofuranes et compositions les comprenant |
DE10237819A1 (de) | 2002-08-19 | 2004-03-04 | Bayer Ag | 5-Nitrobenzofurane |
ATE386034T1 (de) | 2003-07-03 | 2008-03-15 | Aventis Pharma Inc | Pyrazoloisoquinolinenderivaten als kinase inhibitoren |
US20080033209A1 (en) | 2004-08-24 | 2008-02-07 | Basf Aktiengsellschaft | Method For High-Purity Quaternary Ammonium Compounds |
CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物 |
WO2006093801A1 (en) | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
EP1931632A4 (en) | 2005-08-18 | 2011-05-11 | Microbia Inc | USEFUL INDOOR CONNECTIONS |
MX2008011227A (es) | 2006-03-03 | 2009-02-10 | Torrent Pharmaceuticals Ltd | Receptores antagonistas de accion nueva y doble en los receptores at1 y eta. |
WO2007133637A2 (en) | 2006-05-10 | 2007-11-22 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
GB0611210D0 (en) | 2006-06-07 | 2006-07-19 | Cambrex Karlskoga Ab | Process |
GB0719180D0 (en) | 2007-10-02 | 2007-11-14 | Cambrex Karlskoga Ab | New process |
US20120046356A1 (en) | 2008-10-02 | 2012-02-23 | Cambrex Karlskoga Ab | New process for preparing diketones and medicaments |
US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
KR20110081188A (ko) | 2008-10-10 | 2011-07-13 | 론자 리미티드 | 2-알킬-3-아로일-5-니트로-벤조퓨란을 제조하는 방법 |
US20120122971A1 (en) | 2009-04-08 | 2012-05-17 | Cambrex Karlskoga Ab | New process for preparing hydroxylamines and medicaments |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
TW201111354A (en) | 2009-05-27 | 2011-04-01 | Sanofi Aventis | Process for the production of Dronedarone intermediates |
TW201107303A (en) | 2009-05-27 | 2011-03-01 | Sanofi Aventis | Process for the production of benzofurans |
CN101993427B (zh) | 2009-08-26 | 2012-10-10 | 成都伊诺达博医药科技有限公司 | 一种制备决奈达隆的方法 |
HUP0900759A2 (en) | 2009-12-08 | 2011-11-28 | Sanofi Aventis | Novel process for producing dronedarone |
HUP1000010A2 (en) | 2010-01-08 | 2011-11-28 | Sanofi Sa | Process for producing dronedarone |
CN102753018A (zh) * | 2010-02-10 | 2012-10-24 | Mapi医药公司 | 苯并呋喃的制备及其作为合成中间体的用途 |
IT1398317B1 (it) | 2010-02-23 | 2013-02-22 | Chimico Internaz Spa Lab | Nuovo procedimento per la preparazione del dronedarone. |
FR2957079B1 (fr) | 2010-03-02 | 2012-07-27 | Sanofi Aventis | Procede de synthese de derives de cetobenzofurane |
FR2958290B1 (fr) | 2010-03-30 | 2012-10-19 | Sanofi Aventis | Procede de preparation de derives de sulfonamido-benzofurane |
FR2958289B1 (fr) | 2010-03-30 | 2012-06-15 | Sanofi Aventis | Procede de preparation de derives de 3-ceto-benzofurane |
FR2958291B1 (fr) | 2010-04-01 | 2013-07-05 | Sanofi Aventis | Procede de preparation de derives d'amino-benzofurane |
CN101838252B (zh) | 2010-05-27 | 2016-05-04 | 北京德众万全医药科技有限公司 | 2-正丁基-5-取代氨基苯并呋喃及其制备方法 |
HUP1000330A2 (en) | 2010-06-18 | 2011-12-28 | Sanofi Sa | Process for the preparation of dronedarone and the novel intermediates |
WO2012004658A2 (en) | 2010-07-09 | 2012-01-12 | Frichem Private Limited | Process for preparation of n-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]methanesulfonamide, acid addition salts and product thereof |
FR2962731B1 (fr) | 2010-07-19 | 2012-08-17 | Sanofi Aventis | Procede de preparation de derives d'amino-benzoyl-benzofurane |
FR2963006B1 (fr) | 2010-07-21 | 2013-03-15 | Sanofi Aventis | Procede de preparation de derives de nitro-benzofurane |
HUP1000386A2 (en) | 2010-07-22 | 2012-05-29 | Sanofi Sa | Novel process for producing dronedarone |
WO2012032545A1 (en) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Processes for preparing dronedarone and its intermediates |
FR2973027A1 (fr) | 2011-03-24 | 2012-09-28 | Sanofi Aventis | Procede de synthese de derives de cetobenzofurane |
HUP1100166A2 (en) | 2011-03-29 | 2012-12-28 | Sanofi Sa | Reductive amination process for preparation of dronedarone using amine intermediary compound |
HUP1100165A2 (en) | 2011-03-29 | 2012-12-28 | Sanofi Sa | Process for preparation of dronedarone by n-butylation |
HUP1100167A2 (en) | 2011-03-29 | 2012-11-28 | Sanofi Sa | Process for preparation of dronedarone by mesylation |
WO2013014478A1 (en) | 2011-07-26 | 2013-01-31 | Sanofi | Reductive amination process for preparation of dronedarone using carboxyl intermediary compound |
WO2013014479A1 (en) | 2011-07-26 | 2013-01-31 | Sanofi | Reductive animation process for preparation of dronedarone using aldehyde intermediary compound |
WO2013014480A1 (en) | 2011-07-26 | 2013-01-31 | Sanofi | Process for preparation of dronedarone using amide intermediary compound |
FR2983198B1 (fr) | 2011-11-29 | 2013-11-15 | Sanofi Sa | Procede de preparation de derives de 5-amino-benzoyl-benzofurane |
EP2617718A1 (en) | 2012-01-20 | 2013-07-24 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
-
2010
- 2010-06-18 HU HU1000330A patent/HUP1000330A2/hu unknown
-
2011
- 2011-05-30 TW TW100118793A patent/TW201200506A/zh unknown
- 2011-06-10 SG SG2012090692A patent/SG186260A1/en unknown
- 2011-06-10 BR BR112012032358A patent/BR112012032358A2/pt not_active IP Right Cessation
- 2011-06-10 WO PCT/HU2011/000054 patent/WO2011158050A1/en active Application Filing
- 2011-06-10 MX MX2012014675A patent/MX2012014675A/es not_active Application Discontinuation
- 2011-06-10 AU AU2011266805A patent/AU2011266805A1/en not_active Abandoned
- 2011-06-10 EP EP11730061.6A patent/EP2582685A1/en not_active Withdrawn
- 2011-06-10 RU RU2013102259/04A patent/RU2013102259A/ru not_active Application Discontinuation
- 2011-06-10 JP JP2013514790A patent/JP2013528641A/ja not_active Withdrawn
- 2011-06-10 CA CA2802918A patent/CA2802918A1/en not_active Abandoned
- 2011-06-10 CN CN2011800400348A patent/CN103068810A/zh active Pending
- 2011-06-10 KR KR1020137001314A patent/KR20130036282A/ko not_active Application Discontinuation
- 2011-06-17 AR ARP110102110A patent/AR082006A1/es unknown
-
2012
- 2012-12-12 US US13/711,891 patent/US9174958B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013528641A (ja) | 2013-07-11 |
WO2011158050A1 (en) | 2011-12-22 |
CN103068810A (zh) | 2013-04-24 |
RU2013102259A (ru) | 2014-07-27 |
US9174958B2 (en) | 2015-11-03 |
AR082006A1 (es) | 2012-11-07 |
BR112012032358A2 (pt) | 2016-11-08 |
KR20130036282A (ko) | 2013-04-11 |
US20130109868A1 (en) | 2013-05-02 |
AU2011266805A1 (en) | 2013-01-10 |
HUP1000330A2 (en) | 2011-12-28 |
HU1000330D0 (en) | 2010-08-30 |
CA2802918A1 (en) | 2011-12-22 |
EP2582685A1 (en) | 2013-04-24 |
MX2012014675A (es) | 2013-01-22 |
SG186260A1 (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201200506A (en) | Novel process | |
US9174959B2 (en) | Process for preparation of dronedarone by N-butylation | |
TW201144291A (en) | New process for the preparation of dronedarone | |
CA2584775A1 (en) | Asymmetric synthesis of dihydrobenzofuran derivatives | |
JP2008517919A (ja) | 置換ジヒドロベンゾフランの不斉合成 | |
JP2014514291A (ja) | メシル化によるドロネダロンの製造方法 | |
JP2013521264A (ja) | ケトベンゾフラン誘導体、その合成方法および中間体 | |
CA2794576A1 (fr) | Procede de preparation de derives de 3-ceto-benzofurane | |
US20140018554A1 (en) | Reductive amination process for preparation of dronedarone using amine intermediary compound | |
JP5208239B2 (ja) | アルキンカップリングによる抗がん活性三環式化合物の新規製法 | |
WO2013128294A2 (en) | Process for preparation of dronedarone by the use of dibutylaminoethanol reagent | |
CA2787551A1 (en) | Preparation of benzofurans and use thereof as synthetic intermediates | |
JPS5943467B2 (ja) | トランス−ヘキサヒドロジベンゾ〔b,d〕ピラン−9−オン類の製造法 | |
TW201219381A (en) | Novel process for the preparation of dronedarone | |
WO2013014479A1 (en) | Reductive animation process for preparation of dronedarone using aldehyde intermediary compound | |
CN108997242B (zh) | 取代苯基吡唑啉酮衍生物及制备和应用 | |
JP2017530998A (ja) | 1−(3,5−ジクロロフェニル)−2,2,2−トリフルオロ−エタノン及びその誘導体の製造方法 | |
CA2815918A1 (en) | Process for the preparation of 3-aroyl-5-aminobenzofuran derivatives | |
KR20140020981A (ko) | 메실화에 의한 드로네다론의 제조방법 | |
KR20120094090A (ko) | 드로네다론을 제조하기 위한 신규한 방법 |